The Safety and Efficacy of AF-219 in Female Subjects With Interstitial Cystitis /Bladder Pain Syndrome.

Trial Profile

The Safety and Efficacy of AF-219 in Female Subjects With Interstitial Cystitis /Bladder Pain Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2017

At a glance

  • Drugs Gefapixant (Primary)
  • Indications Interstitial cystitis; Pain
  • Focus Therapeutic Use
  • Sponsors Afferent Pharmaceuticals
  • Most Recent Events

    • 09 Oct 2015 Results presented at the 45th Annual Meeting of the International Continence Society
    • 26 Feb 2015 According to an Afferent Pharmaceuticals media release, the results of this trial were presented at the 2015 Society of Urodynamics, Female Pelvic Medicine and Urogential Reconstruction Meeting.
    • 26 Feb 2015 Results published in an Afferent Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top